OBJECTIVE: To evaluate the effect of repeated mass drug administration (MDA) of azithromycin in the Gambia on the nasopharyngeal carriage of Streptococcus pneumoniae and on the emergence of antibiotic-resistant strains. METHODS: This study involved villages that participated in a cluster randomized trial comparing the effect of one versus three azithromycin MDA rounds on the prevalence of trachoma. Only villages in which most children received 7-valent pneumococcal conjugate vaccine were included. Three cross-sectional surveys were performed in two villages that received three annual MDA rounds: the first immediately before the third MDA round and the second and third, 1 and 6 months, respectively, after the third MDA round. The third survey also covered six villages that had received one MDA round 30 months previously. Pneumococcal carriage was assessed using nasopharyngeal swabs and azithromycin resistance was detected using the Etest. FINDINGS: The prevalence of pneumococcal carriage decreased from 43.4% to 19.2% between the first and second surveys (P < 0.001) but rebounded by the third survey (45.8%; P = 0.591). Being a carrier at the first survey was a risk factor for being a carrier at the second (odds ratio: 3.71; P < 0.001). At the third survey, the prevalence of carriage was similar after one and three MDA rounds (50.3% versus 45.8%, respectively; P = 0.170), as was the prevalence of azithromycin resistance (0.3% versus 0.9%, respectively; P = 0.340). CONCLUSION: Three azithromycin MDA rounds did not increase the prevalence of nasopharyngeal carriage of azithromycin-resistant S. pneumoniae strains compared with one round.
OBJECTIVE: To evaluate the effect of repeated mass drug administration (MDA) of azithromycin in the Gambia on the nasopharyngeal carriage of Streptococcus pneumoniae and on the emergence of antibiotic-resistant strains. METHODS: This study involved villages that participated in a cluster randomized trial comparing the effect of one versus three azithromycin MDA rounds on the prevalence of trachoma. Only villages in which most children received 7-valent pneumococcal conjugate vaccine were included. Three cross-sectional surveys were performed in two villages that received three annual MDA rounds: the first immediately before the third MDA round and the second and third, 1 and 6 months, respectively, after the third MDA round. The third survey also covered six villages that had received one MDA round 30 months previously. Pneumococcal carriage was assessed using nasopharyngeal swabs and azithromycin resistance was detected using the Etest. FINDINGS: The prevalence of pneumococcal carriage decreased from 43.4% to 19.2% between the first and second surveys (P < 0.001) but rebounded by the third survey (45.8%; P = 0.591). Being a carrier at the first survey was a risk factor for being a carrier at the second (odds ratio: 3.71; P < 0.001). At the third survey, the prevalence of carriage was similar after one and three MDA rounds (50.3% versus 45.8%, respectively; P = 0.170), as was the prevalence of azithromycin resistance (0.3% versus 0.9%, respectively; P = 0.340). CONCLUSION: Three azithromycin MDA rounds did not increase the prevalence of nasopharyngeal carriage of azithromycin-resistant S. pneumoniae strains compared with one round.
Authors: Dianne Stare; Emma Harding-Esch; Beatriz Munoz; Robin Bailey; David Mabey; Martin Holland; Charlotte Gaydos; Sheila West Journal: Ophthalmic Epidemiol Date: 2011-02 Impact factor: 1.648
Authors: A J Leach; T M Shelby-James; M Mayo; M Gratten; A C Laming; B J Currie; J D Mathews Journal: Clin Infect Dis Date: 1997-03 Impact factor: 9.079
Authors: Sarah L Batt; Bambos M Charalambous; Anthony W Solomon; Charles Knirsch; Patrick A Massae; Salesia Safari; Noel E Sam; Dean Everett; David C W Mabey; Stephen H Gillespie Journal: Antimicrob Agents Chemother Date: 2003-09 Impact factor: 5.191
Authors: Philip C Hill; Abiodun Akisanya; Kawsu Sankareh; Yin Bun Cheung; Mark Saaka; George Lahai; Brian M Greenwood; Richard A Adegbola Journal: Clin Infect Dis Date: 2006-08-04 Impact factor: 9.079
Authors: Emma M Harding-Esch; Tansy Edwards; Harran Mkocha; Beatriz Munoz; Martin J Holland; Sarah E Burr; Ansumana Sillah; Charlotte A Gaydos; Dianne Stare; David C W Mabey; Robin L Bailey; Sheila K West Journal: PLoS Negl Trop Dis Date: 2010-11-02
Authors: Matthew J Burton; Martin J Holland; Pateh Makalo; Esther A N Aryee; Neal D E Alexander; Ansumana Sillah; Hannah Faal; Sheila K West; Allen Foster; Gordon J Johnson; David C W Mabey; Robin L Bailey Journal: Lancet Date: 2005 Apr 9-15 Impact factor: 79.321
Authors: Holger W Unger; Celestine Aho; Maria Ome-Kaius; Regina A Wangnapi; Alexandra J Umbers; Wanda Jack; Alice Lafana; Audrey Michael; Sarah Hanieh; Peter Siba; Ivo Mueller; Andrew R Greenhill; Stephen J Rogerson Journal: J Clin Microbiol Date: 2015-02-11 Impact factor: 5.948
Authors: Jeremy D Keenan; Ida Sahlu; Lesley McGee; Vicky Cevallos; Jorge E Vidal; Sopio Chochua; Paulina Hawkins; Teshome Gebre; Zerihun Tadesse; Paul M Emerson; Bruce D Gaynor; Thomas M Lietman; Keith P Klugman Journal: J Pediatric Infect Dis Soc Date: 2015-01-30 Impact factor: 3.164
Authors: Jennifer R Evans; Anthony W Solomon; Rahul Kumar; Ángela Perez; Balendra P Singh; Rajat Mohan Srivastava; Emma Harding-Esch Journal: Cochrane Database Syst Rev Date: 2019-09-26
Authors: Ebrima Bojang; James Jafali; Vincent Perreten; John Hart; Emma M Harding-Esch; Ansumana Sillah; David C W Mabey; Martin J Holland; Robin L Bailey; Anna Roca; Sarah E Burr Journal: BMC Microbiol Date: 2017-03-28 Impact factor: 3.605
Authors: Rebecca A Gladstone; Ebrima Bojang; John Hart; Emma M Harding-Esch; David Mabey; Ansumana Sillah; Robin L Bailey; Sarah E Burr; Anna Roca; Stephen D Bentley; Martin J Holland Journal: Clin Microbiol Infect Date: 2020-08-01 Impact factor: 8.067
Authors: A Roca; C Oluwalana; A Bojang; B Camara; B Kampmann; R Bailey; A Demba; C Bottomley; U D'Alessandro Journal: Clin Microbiol Infect Date: 2016-03-26 Impact factor: 8.067
Authors: Anna Roca; Abdoulie Bojang; Christian Bottomley; Rebecca A Gladstone; Jane U Adetifa; Uzochukwu Egere; Sarah Burr; Martin Antonio; Stephen Bentley; Beate Kampmann Journal: Vaccine Date: 2015-11-17 Impact factor: 3.641